Evaluation of circulating prognostic tumor marker dna in the blood of brain tumor patients

Roya Taghvamanesh,1,*



Recent evidence suggests that tumor cells may release dna into the circulation, which is enriched in the serum and plasma, allowing detection of p16 and p53 microsatellite alterations in the serum dna of cancer patients. key biomarkers could potentially outweigh traditional radiological or pathological methods by enabling specificity of early detection, when coupled with tumor molecular profiling and clinical associations.


Twenty patients (median age 56 years), undergoing surgery for nervous system tumors (cnsts), and 10 healthy volunteers were included in this study. plasma samples were collected from patients and healthy individuals. qualitative polymerase chain reaction (pcr) were conducted using specific primers for p16 and p53.


The concentration of p53 was significantly increased in plasma of nervous system tumors (cnsts) patients compared to the control group (p = 0.05). interestingly, the concentration of p16 was significantly higher in healthy individuals than patients (p = 0.05). the total cfdna concentration was slightly increased in plasma after the surgery. two patients not included in the analysis (no detect p16 and p53 gene)


According to our results, the concentration of p16 and p53 in cfdna could be a potential biomarker for diagnosis of nervous system tumors (cnsts). these results support the idea that the dna in the circulation of cancer patients could originate from both apoptotic and necrotic cells in cancer tissue. whether the amount of p16 and p53 in cfdna represents a reliable biomarker for early diagnosis has confirm


Prognostic,tumor markers